Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model

被引:54
作者
Tao, D
Barba-Spaeth, G
Rai, U
Nussenzweig, V
Rice, CM
Nussenzweig, RS
机构
[1] Rockefeller Univ, Lab Virol & Infect Dis, New York, NY 10021 USA
[2] NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10016 USA
[3] NYU, Sch Med, Dept Pathol, Michael Heidelberger Div, New York, NY 10016 USA
关键词
D O I
10.1084/jem.20041526
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The yellow fever vaccine 17D (17D) is safe, and after a single immunizing dose, elicits long-lasting, perhaps lifelong protective immunity. One of the major challenges facing delivery of human vaccines in underdeveloped countries is the need for multiple injections to achieve full efficacy. To examine 17D as a vector for microbial T cell epitopes, we inserted the H-2K(d)-restricted CTL epitope of the circumsporozoite protein (CS) of Plasmodium yoelii between 17D nonstructural proteins NS2B and NS3. The recombinant virus, 17D-Py, was replication competent and stable in vitro and in vivo. A single subcutaneous injection of 10(5) PFU diminished the parasite burden in the liver by similar to70%. The high level of protection lasted between 4 and 8 wk after immunization, but a significant effect was documented even 24 wk afterwards. Thus, the immunogenicity of a foreign T cell epitope inserted into 17D mimics some of the remarkable properties of the human vaccine. Priming with 17D-Py followed by boosting with irradiated sporozoites conferred sterile immunity to 90% of the mice. This finding indicates that the immune response of vaccine-primed individuals living in endemic areas could be sustained and magnified by the bite of infected mosquitoes.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 37 条
[1]   Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing [J].
Amberg, SM ;
Rice, CM .
JOURNAL OF VIROLOGY, 1999, 73 (10) :8083-8094
[2]  
[Anonymous], FIELDS VIROLOGY
[3]  
[Anonymous], IMMUNOLOGICAL BASIS
[4]   Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial [J].
Bojang, KA ;
Milligan, PJM ;
Pinder, M ;
Vigneron, L ;
Alloueche, A ;
Kester, KE ;
Ballou, WR ;
Conway, DJ ;
Reece, WHH ;
Gothard, P ;
Yamuah, L ;
Delchambre, M ;
Voss, G ;
Greenwood, BM ;
Hill, A ;
McAdam, KPWJ ;
Tornieporth, N ;
Cohen, JD ;
Doherty, T .
LANCET, 2001, 358 (9297) :1927-1934
[5]   Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus [J].
Bonaldo, MC ;
Garratt, RC ;
Caufour, PS ;
Freire, MS ;
Rodrigeus, MM ;
Nussenzweig, RS ;
Galler, R .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 315 (04) :873-885
[6]   A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication [J].
Bredenbeek, PJ ;
Kooi, EA ;
Lindenbach, B ;
Huijkman, N ;
Rice, CM ;
Spaan, WJM .
JOURNAL OF GENERAL VIROLOGY, 2003, 84 :1261-1268
[7]   Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR [J].
Bruña-Romero, O ;
Hafalla, JCR ;
González-Aseguinolaza, G ;
Sano, G ;
Tsuji, M ;
Zavala, F .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2001, 31 (13) :1499-1502
[8]   ELISPOT assay to measure antigen-specific murine CD8+ T cell responses [J].
Carvalho, LH ;
Hafalla, JCR ;
Zavala, F .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 252 (1-2) :207-218
[9]   Hepatitis and death following vaccination with 17D-204 yellow fever vaccine [J].
Chan, RC ;
Penney, DJ ;
Little, D ;
Carter, IW ;
Roberts, JA ;
Rawlinson, WD .
LANCET, 2001, 358 (9276) :121-122
[10]   Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: Identification of HLA-1335-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E [J].
Co, MDT ;
Terajima, M ;
Cruz, J ;
Ennis, FA ;
Rothman, AL .
VIROLOGY, 2002, 293 (01) :151-163